Zymeworks Share Holder Equity 2016-2022 | ZYME
Zymeworks share holder equity from 2016 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Zymeworks Annual Share Holder Equity
(Millions of US $) |
| 2021 |
$249 |
| 2020 |
$410 |
| 2019 |
$246 |
| 2018 |
$180 |
| 2017 |
$116 |
| 2016 |
$68 |
| 2015 |
$18 |
Zymeworks Quarterly Share Holder Equity
(Millions of US $) |
| 2022-06-30 |
$222 |
| 2022-03-31 |
$282 |
| 2021-12-31 |
$249 |
| 2021-09-30 |
$279 |
| 2021-06-30 |
$321 |
| 2021-03-31 |
$377 |
| 2020-12-31 |
$410 |
| 2020-09-30 |
$432 |
| 2020-06-30 |
$491 |
| 2020-03-31 |
$522 |
| 2019-12-31 |
$246 |
| 2019-09-30 |
$310 |
| 2019-06-30 |
$334 |
| 2019-03-31 |
$170 |
| 2018-12-31 |
$180 |
| 2018-09-30 |
$170 |
| 2018-06-30 |
$186 |
| 2018-03-31 |
$95 |
| 2017-12-31 |
$116 |
| 2017-09-30 |
$83 |
| 2017-06-30 |
$97 |
| 2017-03-31 |
$50 |
| 2016-12-31 |
$68 |
| 2016-09-30 |
$0 |
| 2016-06-30 |
$0 |
| 2016-03-31 |
$0 |
| 2015-12-31 |
$18 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.570B |
$0.412B |
|
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
|
